Status:

APPROVED_FOR_MARKETING

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Lead Sponsor:

Amgen

Conditions:

Small Cell Lung Cancer

Eligibility:

All Genders

18+ years

Brief Summary

The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prio...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years
  • Histologically or cytologically confirmed SCLC
  • Extensive-stage, unable to be encompassed in a tolerable radiation plan
  • Progressed or recurred following 1 platinum-based regimen and at least 1 other prior line of therapy
  • Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1
  • Minimum life expectancy of 12 weeks

Exclusion

  • Any previous diagnosis of transformed non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, or mixed SCLC NSCLC histology
  • Symptomatic central nervous system (CNS) metastases
  • Active hepatitis B or hepatitis C virus infection
  • Eligible for participation in any Amgen-sponsored ongoing clinical study of the investigational product
  • Currently or previously enrolled in a prior tarlatamab study
  • Female participants and/or male participants with female partners who are pregnant, breastfeeding, planning to become pregnant or donate eggs while on study through 60 days after the last dose of tarlatamab
  • Male and female participants unwilling to practice abstinence and/or use protocol specified method of contraception

Key Trial Info

Start Date :

Trial Type :

EXPANDED_ACCESS

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT06064500

Last Update

March 10 2025

Active Locations (23)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (23 locations)

1

Yale School of Medicine

New Haven, Connecticut, United States, 06520

2

Mount Sinai Comprehensive Cancer Center

Miami Beach, Florida, United States, 33140

3

Martin Memorial Health System

Stuart, Florida, United States, 34994

4

Nebraska Cancer Specialists

Omaha, Nebraska, United States, 68106

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer | DecenTrialz